Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure

• MATSUZAKI Masunori

  Department of Medicine and Clinical Science,Division of Cardiology,Yamaguchi University Graduate School of Medicine

• YAMAMOTO Kazuhiro

  Division of Cardiovascular Medicine,Endocrinology and Metabolism,Department of Molecular Medicine and Theerapeutics,Faculty of Medicin,Tottori University

• YANO Masafumi

  Department of Medicine and Clinical Science,Division of Cardiology,Yamaguchi University Graduate School of Medicine

• NAKAMURA Koki

  Pharmaceutical Development Division,Takeda Pharmaceutical Company Limited

• MIYATA Yuko

  Pharmaceutical Development Division,Takeda Pharmaceutical Company Limited

• SUGIURA Kenkichi

  Pharmaceutical Development Division,Takeda Pharmaceutical Company Limited

• NAKATA Emi

  Pharmaceutical Development Division,Takeda Pharmaceutical Company Limited

• TSUTSUI Hiroyuki

  Department of Cardiovascular Medicine,Hokkaido University Graduate School of Medicine

Journal

• J Cardiol

  J Cardiol 61 (3), 267-274, 2013-04-10

Keywords

• Candeartan
• Heart failure
• Angiotensin II receptor blocker
• Brain natriuretic peptide
• Left ventricular ejection fraction

Details

• CRID: 1572824501002543488
• NII Article ID: 10031187799
• NII Book ID: AN10070473
• ISSN: 09145087
• Web Site: https://search.jamas.or.jp/link/ui/2014070366
• Text Lang: en
• Data Source:
  • CiNii Articles